http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
[PE-0061] Advancement potato breeding for French fries from 2019 to 2021
Jang Gyu Choi(Jang Gyu Choi),Yong Ik Jin(Yong Ik Jin),Gyu Bin Lee(Gyu Bin Lee),Jung Gun Ho(Jung Gun Ho),Do Hee Kwon(Do Hee Kwon),Kwang Ryong Cho(Kwang Ryong Cho),Chung Ki Choen(Chung Ki Choen),Yeong E 한국육종학회 2022 한국육종학회 공동학술발표집 Vol.2022 No.-
The Benefits of Bisoprolol were Comparable with Carvedilol in Secondary Prevention of Acute MI
( Gyu Ik Lee ),( Wan Kim ),( Sun Ho Hwang ),( Won Yu Kang ),( Sang Cheol Cho ),( Kyung Hwan Kim ),( Young Eun Jo ),( Sang Woo Jeong ),( Myung Ho Jeong ),( Young Keun Ahn ) 대한내과학회 2015 대한내과학회 추계학술대회 Vol.2015 No.1
Objective: Although the benefits of carvedilol, non-cardioselective Β-blocker, were demonstrated by several studies, there were no studies which evaluated the efficacy of bisoprolol, a class of Β1-selective beta blocker, in secondary prevention of acute myocardial infarction(MI) patients who underwent percutaneous coronary intervention (PCI). Methods: Total 13,813 patients who underwent PCI were treated with carvedilol or bisoprolol at discharge in Korean Acute MI Registry (KAMIR). After 1: 2 propensity matching, 1,806 patients were enrolled as bisoprolol group and 3,612 patients as carvedilol group. The primary end point was composite of major adverse cardiac events (MACEs)which were defined as cardiac death, non-fatal MI, target vessel revascularization, and coronary artery bypass surgery. The secondary end point was defined as respective all-cause mortality, cardiac death, non-fatal MI, any revascularization or target vessel revascularization. Results: After adjustment of baseline characteristics by propensity matching, the MACEs free survival rate was not different between bisoprolol and carvedilol group. The subgroup analysis showed that cumulative incidence of MACEs was lower in bisoprolol group in patients having Killip class III or IV comparing with carvedilol group. The incidence of secondary end points was not different between two groups. Conclusions: The benefits of bisoprolol were comparable with carvedilol in secondary prevention of acute MI. The use of bisoprolol may be preferable in hemodynamically unstable acute MI patients on admission.
( Gyu Cheol Lee ),( Min Jeong Kim ),( Jong Ik Kim ),( Chan Hee Lee ) 한국미생물 · 생명공학회 2014 Journal of microbiology and biotechnology Vol.24 No.4
The occurrence of human norovirus (NoV) genogroup I (GI) and genogroup II (GII) strains was investigated in Korea. Between 2007 and 2010, 265 samples were collected from 89 Korean water source locations. NoV GI was detected in 4.5% and NoV GII in 1.5%. Samples collected in winter had the highest occurrence; 9.4% for NoV GI and 6.3% for NoV GII. NoV GI detection was highest in groundwater, with the next highest in river water and the lowest in lake water (5.9%, 5.4%, and 1.6%, respectively), and NoV GII was found only in river water. When three representative Korean basin systems (Han (H)-, Geum/Seom (G/S)-, and Nakdong (N)-river basins) were compared, both NoV genogroups were high in the G/S-, but absent in the H- river basin. The most prevalent genotypes within the GI and GII groups were GI.5 and GII.4, respectively. The NoVs found in surface water were identical to those found in patients and those found in groundwater. The NoVs appeared to be transmitted from the patient to the surface water, and then to the groundwater, suggesting a fecal-oral route of transmission. This is the first nationwide surveillance of NoV in major Korean water sources.
Early versus Late Thrombolysis in Acute Arterial Occlusion
( Gyu Ik Lee ),( Wan Kim ),( Sun Ho Hwang ),( Won Yu Kang ),( Sang Cheol Cho ),( Young Eun Jo ),( Sang Woo Jeong ) 대한내과학회 2015 대한내과학회 추계학술대회 Vol.2015 No.1
Background: Acute arterial occlusion of extremities is defined as 14 days or less of duration after onset of symptoms for arterial occlusion. This study was designed to study the efficacy of an early thrombolysis compared with a late thrombolysis in patient with acute arterial occlusion. Methods: We identified all patients discharged from the Gwangju Veterans hospital with a diagnosis of acute arterial occlusion between 2006 and 2014. Total 72 patients received urgent catheter-directed thrmbolysis therapy using urokinase for acute arterial occlusion. The early thrombolysis group ((less than 7 days after the onset of symptoms) was 42 and the late thrombolysis group (7 to 14 days after the onset of symptoms) was 30. The primary outcome was amputation rate at 180 days and the secondary outcomes were all cause mortality at 180days and the increase of ankle brachial blood-pressure index (ABI). Results: Age (74.7 ± 9.4 vs. 75.5 ± 9.5, p=0.729) and sex (95.2% and 100% of male, p=0.225) were not different between two group. There were no significant difference in prevalence of hypertension, diabetes mellitus, dyslipidemia, smoking, peripheral artery disease, coronary artery disease. Amputation rate at 180 days was lower in early thrombolysis group (7.1% vs. 30.0%, p=0.010). The prevalence of atrial fibrillation was higher in early thrombolysis group (40.5% vs. 10.7%, p=0.031). There was no significant difference in mortality rate (16.7% vs. 16.7%, p=1.0) and the increase of ABI (0.69 ± 0.28 vs. 0.60 ± 0.36, p=0.272). In multivariable cox-regression analysis, early thrombolysis reduced the amputation rate at 180 days (HR =0.155, 95% CI=0.034-0.707, p=0.016) Conclusions: Early thrombolysis did differ greatly from late thrombolysis in preventing amputation rate in patients with acute arterial occlusion.
( Dong Gyu Lee ),( Kil Jong Yu ),( Dae Hyeon Cho ),( Ji Enu Oh ),( Chang Wook Jeong ),( Kwang Min Kim ),( Hyoun Soo Lee ),( Jung Won Lee ),( Ik Sung Choi ),( Byung Soo Kwan ),( Sang Goon Shim ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Direct Anti-viral Agent (DAA) has Obtained new indications of treating hepatitis C virus. Various DAA treatment regimens are selected by HCV genotype. Dermatological side effects after sofosbuvir and daclatasvir combination are rare worldwide. Results: We report a case of cutaneous erythema which occurred after treatment of sofoubuvir and daclatasvir for hepatitis C genotype 3 treatment. The 91-year-old male patient visited our clinic complaining of new skin lesions. He was diagnosed with genotype 3a chronic hepatitis C by genetic test. Abdominal ultrasonography shows chronic hepatitis without cirrhosis. Trans Elestography showed F2, which meant that the patient had chronic hepatitis without cirrhosis. Patient was generally good condition. We started treatment daily with sofosbuvir 400mg and daclatasvir 60mg. Then, 56 days later, multiple erythematous scaly patches appeared on the patient’s trunk and pelvis. He had no itching and was kept in good condition. The score of Naranjo ADR probability scale was 7, which indicated probable. The patient’s skin lesions notably improved after the medications were terminated. Finally, the patient obtained SVR 12. Conclusions: In treatment of hepatitis C, the rate of dermatologic side effects by DAA treatment is known around 3-8%, usually. Although in severe cases, there was a case of DRESS. However, in this case, only slight skin patches were observed. The skin side effects by DAA treatment are very rare. And this is the first report of dermatological side effects after sofosbuvir and daclatasvir combination therapy in Korea. More attention needs to be paid to prescribing DAA in the treatment of chronic hepatitis C.
One Million Cycle Durability Test of Electrochromic Devices Using Charge Balance Control
In-Gyu Choi,Dahyun Choi,Jang-Yeob Lee,Minji Lee,Sung-Ik Park,Doo-Man Chun,Caroline Sunyong Lee,Won-Shik Chu 한국정밀공학회 2020 International Journal of Precision Engineering and Vol.7 No.1
We fabricated 10 mm × 10 mm WO3 electrochromic devices (ECDs) using a nanoparticle deposition system (NPDS), which is a coating method that uses kinetic spray. NPDS has the advantage of mass production due to its relatively low pressure and low temperature working conditions but can result in porous surfaces, which has a negative effect on device durability. We developed an optical transmittance measurement and voltage control system that allows dynamic control. Transmittance was measured by Optical Power Meter, 2936-R Newport, while voltage was dynamically applied by NI9477, National Instrument. Current was measured by high resolution current, National Instrument. This system enables ECDs to be feedback controlled depending on the measured electronic properties. We then characterized the WO3 ECDs, focusing on the relationship between transmittance and current under well-known static operating conditions. Finally, we proposed a new algorithm to extend durability performance by adopting charge balance control and conducted an accelerated life test over 1,000,000 cycles. According to our results, the optical performance was maintained until the test ended, and there was a 45.4% difference in the maximum and minimum transmittance of the sample after the accelerated life test. Therefore, the charge balance control enhanced the lifetime of the ECDs by avoiding negative charge accumulation, verifying that the durability of ECDs could be enhanced by adopting dynamic control.